Cabergoline treatment of pregnant women with macroprolactinomas.
Laloi-Michelin
M
M
AP-HP, Hôpital Lariboisière, Service de Médecine Interne B, Paris, France. marie.laloi-michelin@lrb.aphp.fr
Ciraru-Vigneron
N
N
Meas
T
T
D000077465:Cabergoline; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D004873:Ergolines / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010911:Pituitary Neoplasms / Q000188:drug therapy*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D011256:Pregnancy Outcome; D015175:Prolactinoma / Q000188:drug therapy*; D016896:Treatment Outcome
D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline